Skip to main content
Top
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study

Authors: Alicia H Chang, Andrea Polesky, Gulshan Bhatia

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

Patient adherence to isoniazid (INH) monotherapy for latent tuberculosis infection (LTBI) has been suboptimal despite its proven efficacy. Various strategies have been studied to improve adherence, but all have been based at a clinic or treatment program. At the Santa Clara Valley Tuberculosis Clinic, it was our practice to refer a subset of high-risk LTBI patients to the Public Health Department for monthly follow-up at home instead of at the clinic. Our goal was to assess whether house calls by community health workers and public health nurses affected INH adherence or frequency of adverse effects.

Methods

We retrospectively studied 3918 LTBI patients who received INH. At the discretion of the treating physician, 986 (25.2%) received house calls instead of clinic follow-up. Home-based follow-up included language translation, medication delivery, assessment of compliance with pill counts, monitoring for adverse effects, and active tracking of noncompliant patients. We assessed differences in patient characteristics, treatment completion, and reasons for treatment discontinuation between patients followed at home versus in the clinic. Multivariate analyses to address possible referral bias or confounding were performed using logistic regression.

Results

More patients followed with house calls completed INH treatment (90% home versus 73.2% clinic). This was the case across all subgroups of patients, including those with historically the lowest adherence: patients from correctional and rehabilitation facilities (77.8% home versus 46.9% clinic), postpartum women (86.4% home versus 55.6% clinic), and patients aged between 18 and 35 years (87% home versus 63.1% clinic). After adjusting for age, place of birth, referral category (TB contacts/skin test converters, correctional/rehabilitation patients, postpartum women, tuberculin positive patients from other screening), and prescribed INH regimen duration (9 versus 6 months), home-based follow-up of LTBI patients was a significant predictor of treatment completion (AOR 2.94, 95% CI: 2.33, 3.71). Patients followed at home were 21% more likely to complete therapy (ARR 1.21, p<0.001). Risk of adverse effects was similar between the two types of follow-up.

Conclusion

Home-based follow-up of LTBI patients taking isoniazid was associated with improved treatment completion and no increase in adverse effects regardless of patient characteristics or prescribed duration of INH therapy.
Literature
1.
go back to reference Targeted tuberculin testing and treatment of latent tuberculosis infection: American thoracic society. MMWR Recomm Rep. 2000, 49 (RR-6): 1-51. Targeted tuberculin testing and treatment of latent tuberculosis infection: American thoracic society. MMWR Recomm Rep. 2000, 49 (RR-6): 1-51.
2.
go back to reference Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibliotheca tuberculosea. 1970, 26: 28-106.PubMed Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibliotheca tuberculosea. 1970, 26: 28-106.PubMed
3.
go back to reference Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial: international union against tuberculosis committee on prophylaxis. Bull World Health Organ. 1982, 60 (4): 555-564. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial: international union against tuberculosis committee on prophylaxis. Bull World Health Organ. 1982, 60 (4): 555-564.
4.
go back to reference Comstock GW: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1999, 3 (10): 847-850. Comstock GW: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1999, 3 (10): 847-850.
5.
go back to reference Healthy people 2010, vol. two, second edn. 2000, Washington DC, USA: US Department of Health and Human Services Healthy people 2010, vol. two, second edn. 2000, Washington DC, USA: US Department of Health and Human Services
6.
go back to reference Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008, 12 (11): 1235-1254.PubMed Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008, 12 (11): 1235-1254.PubMed
7.
go back to reference Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al: Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010, 137 (2): 401-409. 10.1378/chest.09-0394.CrossRefPubMed Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al: Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010, 137 (2): 401-409. 10.1378/chest.09-0394.CrossRefPubMed
8.
go back to reference Tulsky JP, Hahn JA, Long HL, Chambers DB, Robertson MJ, Chesney MA, Moss AR: Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis. 2004, 8: 83-91.PubMed Tulsky JP, Hahn JA, Long HL, Chambers DB, Robertson MJ, Chesney MA, Moss AR: Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis. 2004, 8: 83-91.PubMed
9.
go back to reference Last JP, Kozakiewicz JM: Development of a pharmacist-managed latent tuberculosis clinic. Am J Health Syst Pharm. 2009, 66 (17): 1522-1523. 10.2146/ajhp090034.CrossRefPubMed Last JP, Kozakiewicz JM: Development of a pharmacist-managed latent tuberculosis clinic. Am J Health Syst Pharm. 2009, 66 (17): 1522-1523. 10.2146/ajhp090034.CrossRefPubMed
10.
go back to reference White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E: Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002, 162 (9): 1044-1050. 10.1001/archinte.162.9.1044.CrossRefPubMed White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E: Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002, 162 (9): 1044-1050. 10.1001/archinte.162.9.1044.CrossRefPubMed
11.
go back to reference Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174 (8): 935-952. 10.1164/rccm.200510-1666ST.CrossRefPubMed Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174 (8): 935-952. 10.1164/rccm.200510-1666ST.CrossRefPubMed
12.
go back to reference Zhang J, Yu KF: What’s The relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA: the journal of the American Medical Association. 1998, 280 (19): 1690-1691. 10.1001/jama.280.19.1690.CrossRefPubMed Zhang J, Yu KF: What’s The relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA: the journal of the American Medical Association. 1998, 280 (19): 1690-1691. 10.1001/jama.280.19.1690.CrossRefPubMed
13.
go back to reference Daly LE: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol. 1998, 147 (8): 783-790. 10.1093/oxfordjournals.aje.a009523.CrossRefPubMed Daly LE: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol. 1998, 147 (8): 783-790. 10.1093/oxfordjournals.aje.a009523.CrossRefPubMed
14.
go back to reference Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988, 75 (4): 800-802. 10.1093/biomet/75.4.800.CrossRef Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988, 75 (4): 800-802. 10.1093/biomet/75.4.800.CrossRef
15.
go back to reference Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA: the journal of the American Medical Association. 1986, 256 (19): 2709-2713. 10.1001/jama.1986.03380190079029.CrossRefPubMed Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA: the journal of the American Medical Association. 1986, 256 (19): 2709-2713. 10.1001/jama.1986.03380190079029.CrossRefPubMed
16.
go back to reference Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS: A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in Central Massachusetts. Clin Infect Dis. 2009, 49 (3): 424-427. 10.1086/600394.CrossRefPubMed Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS: A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in Central Massachusetts. Clin Infect Dis. 2009, 49 (3): 424-427. 10.1086/600394.CrossRefPubMed
17.
go back to reference Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006, 166 (17): 1863-1870. 10.1001/archinte.166.17.1863.CrossRefPubMed Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006, 166 (17): 1863-1870. 10.1001/archinte.166.17.1863.CrossRefPubMed
18.
go back to reference Holland DP, Sanders GD, Hamilton CD, Stout JE: Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009, 179 (11): 1055-1060. 10.1164/rccm.200901-0153OC.CrossRefPubMedPubMedCentral Holland DP, Sanders GD, Hamilton CD, Stout JE: Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009, 179 (11): 1055-1060. 10.1164/rccm.200901-0153OC.CrossRefPubMedPubMedCentral
19.
go back to reference Menzies D, Al Jahdali H, Al Otaibi B: Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011, 133: 257-266.PubMedPubMedCentral Menzies D, Al Jahdali H, Al Otaibi B: Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011, 133: 257-266.PubMedPubMedCentral
20.
go back to reference Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al: Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England journal of medicine. 2011, 365 (23): 2155-2166. 10.1056/NEJMoa1104875.CrossRefPubMed Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al: Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England journal of medicine. 2011, 365 (23): 2155-2166. 10.1056/NEJMoa1104875.CrossRefPubMed
21.
go back to reference Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE: New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine. 2011, 365 (1): 11-20. 10.1056/NEJMoa1005136.CrossRefPubMedPubMedCentral Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE: New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine. 2011, 365 (1): 11-20. 10.1056/NEJMoa1005136.CrossRefPubMedPubMedCentral
22.
go back to reference Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. Morbidity and mortality weekly report. 2011, 60 (48): 1650-1653. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. Morbidity and mortality weekly report. 2011, 60 (48): 1650-1653.
23.
go back to reference Holland D, Sanders G, Hamilton C, Stout J: Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS ONE. 2011, 6 (7): e22276-e22276. 10.1371/journal.pone.0022276.CrossRefPubMedPubMedCentral Holland D, Sanders G, Hamilton C, Stout J: Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS ONE. 2011, 6 (7): e22276-e22276. 10.1371/journal.pone.0022276.CrossRefPubMedPubMedCentral
24.
go back to reference Portilla J, Jorda P, Esteban J, Sanchez-Paya J, Merino E, Boix V, Grupo de Estudio Protocolo INH: Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens. Enfermedades infecciosas y microbiologia clinica. 2003, 21 (6): 293-295.CrossRefPubMed Portilla J, Jorda P, Esteban J, Sanchez-Paya J, Merino E, Boix V, Grupo de Estudio Protocolo INH: Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens. Enfermedades infecciosas y microbiologia clinica. 2003, 21 (6): 293-295.CrossRefPubMed
25.
go back to reference Schumann A, Nyamathi A, Stein JA: HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. J Health Psychol. 2007, 12 (5): 833-843. 10.1177/1359105307080618.CrossRefPubMed Schumann A, Nyamathi A, Stein JA: HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. J Health Psychol. 2007, 12 (5): 833-843. 10.1177/1359105307080618.CrossRefPubMed
26.
go back to reference Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B: Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. [Article]. Nurs Res. 2008, 57 (1): 33-39. 10.1097/01.NNR.0000280660.26879.38.CrossRefPubMedPubMedCentral Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B: Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. [Article]. Nurs Res. 2008, 57 (1): 33-39. 10.1097/01.NNR.0000280660.26879.38.CrossRefPubMedPubMedCentral
27.
go back to reference Dobler C, Marks G: Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS ONE. 2012, 7 (11): e48900-e48900. 10.1371/journal.pone.0048900.CrossRefPubMedPubMedCentral Dobler C, Marks G: Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS ONE. 2012, 7 (11): e48900-e48900. 10.1371/journal.pone.0048900.CrossRefPubMedPubMedCentral
28.
go back to reference Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA : the journal of the American Medical Association. 1999, 281 (11): 1014-1018. 10.1001/jama.281.11.1014.CrossRefPubMed Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA : the journal of the American Medical Association. 1999, 281 (11): 1014-1018. 10.1001/jama.281.11.1014.CrossRefPubMed
Metadata
Title
House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study
Authors
Alicia H Chang
Andrea Polesky
Gulshan Bhatia
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-894

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue